Melphalan Flufenamide (Melflufen, PEPAXTO®) is a peptide-drug conjugate (PDC) that uses specific enzymes that are produced in large amounts by myeloma cells. Once the drug enters the cell, it delivers a toxic payload to attack the cancer cell.
On October 22, 2021, Oncopeptides AB announced that the company has decided to withdraw Pepaxto® (INN melphalan flufenamide) from the market in the US. Learn more
|Developed By||Oncopeptides AB|
|Generic Name||Melphalan Flufenamide (Melflufen)|
December 09, 2020
The phase 2 HORIZON data are the basis for the ongoing priority review of the New Drug Application to the US Food and Drug Administration FDA, for accelerated approval of melflufen in combination with dexamethasone in triple-class refractory multiple myeloma patients, who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 monoclonal antibody.